

ADVERTISEMENT

**EBioMedicine**  
Supported by **CoPress** | THE LANCET

 Stay current with the new app  
FOR iOS AND ANDROID

[LEARN MORE](#)

[Home](#) [Journals](#) [Specialties](#) [The Lancet Clinic](#) [Global Health](#) [Multimedia](#) [Campaigns](#) [More](#) [Information for](#)

[Submit a Paper](#)

# THE LANCET

## Respiratory Medicine



[Login](#) | [Register](#) | [Subscribe](#)

[Online First](#) [Current Issue](#) [All Issues](#) [Multimedia](#) [Information for Authors](#) [Advisory Board](#)

[All Content](#)

[Search](#) [Advanced Search](#)

[< Previous Article](#)

**Online First**

[Next Article >](#)








Access this article on [ScienceDirect](#)

Articles

## Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study

Dr [Matthew R Moore](#), MD, [Ruth Link-Gelles](#), PhD, Prof [William Schaffner](#), MD, [Ruth Lynfield](#), MD, [Corinne Holtzman](#), MPH, Prof [Lee H Harrison](#), MD, [Shelley M Zansky](#), PhD, [Jennifer B Rosen](#), MD, Prof [Arthur Reingold](#), MD, [Karen Scherzinger](#), MPH, [Ann Thomas](#), MD, [Ramon E Guevara](#), PhD, [Tasneem Motala](#), MPH, [Jeffrey Eason](#), MPH, [Meghan Barnes](#), MSPH, [Susan Petit](#), MPH, Prof [Monica M Farley](#), MD, [Lesley McGee](#), PhD, Prof [James H Jorgensen](#), MD, [Cynthia G Whitney](#), MD

### Article Options

-  [PDF \(186 KB\)](#)
-  [Download Images\(.ppt\)](#)
- 
-  [Email Article](#)
-  [Add to My Reading List](#)
-  [Export Citation](#)
-  [Create Citation Alert](#)
-  [Cited by in Scopus \(0\)](#)

The best science for better lives

[Article Info](#)[Summary](#) [Full Text](#) [Tables and Figures](#) [References](#) [Supplementary Material](#)

## Summary

### Background

In 2010, 13-valent pneumococcal conjugate vaccine (PCV13) was licensed and recommended in the USA for prevention of invasive pneumococcal disease in children. Licensure was based on immunogenicity data comparing PCV13 with the earlier seven-valent formulation. Because clinical endpoints were not assessed for the new antigens, we did a postlicensure matched case-control study to assess vaccine effectiveness.

### Methods

Cases in children aged 2–59 months were identified through active surveillance in 13 sites. Controls were identified via birth registries and matched to cases by age and postal (zip) code. The primary objective was the vaccine effectiveness of at least one dose against the 13 serotypes included in PCV13. Secondary objectives included vaccine effectiveness against all-cause invasive pneumococcal disease, against antibiotic non-susceptible invasive pneumococcal disease, and among children with and without underlying conditions. Vaccine effectiveness was calculated as  $(1 - \text{matched odds ratio}) \times 100\%$ .

### Findings

We enrolled 722 children with invasive pneumococcal disease and 2991 controls; PCV13 serotype cases (217 [30%]) included most commonly serotypes 19A (128 [18%]), 7F (32 [4%]), and 3 (43 [6%]). Vaccine effectiveness against PCV13 serotypes was 86.0% (95% CI 75.5 to 92.3), driven by serotypes 19A and 7F, for which vaccine effectiveness was 85.6% (95% CI 70.6 to 93.5) and 96.5% (82.7 to 100), respectively. We also identified statistically significant effectiveness against serotype 3 (79.5%, 95% CI 30.3 to 94.8) and against antibiotic non-susceptible invasive pneumococcal disease (65.6%, 44.9 to 78.7). Vaccine effectiveness against all-cause invasive pneumococcal disease was 60.2% (95% CI 46.8 to 70.3). Vaccine effectiveness was similar among children with (81.4%, 95% CI 45.4 to 93.6) and without (85.8%, 74.9 to 91.9) underlying conditions.

### Interpretation

PCV13 appears highly effective against invasive pneumococcal disease among children in the USA in the context of routine and catch-up schedules, although some new vaccine antigens could not be assessed. PCV13 immunisation provides a robust strategy for combating pneumococcal antimicrobial resistance.

### Funding

Centers for Disease Control and Prevention.

To read this article in full you will need to make a payment

Already registered? Please login.

Email/Username:

Password:

Remember me

#### Payment Options

- **Purchase this article for \$31.50 USD**
  - Online access for 24 hours
  - PDF version can be downloaded as your permanent record

#### Subscribe to The Lancet Respiratory Medicine

**Purchase a subscription** to gain access to this and all other articles in

The best science is a good start

#### The Lancet's Manifesto

We at *The Lancet* believe it is our moral imperative to empower research and to grow the social impact of science.

Improving lives is the only end goal that matters, and research is only relevant when it has impact on human lives. We therefore select only the best research papers, based on their quality of work and the progression they bring: the best science for better lives.

[Find out more about The Lancet's vision](#)

[Forgot password?](#)

**Register**

[Create a new account](#)

this journal.

**Options include:**

- [Personal online only subscription](#)

**Institutional Access**

Visit [ScienceDirect](#) to see if you have access via your institution.

**Already a print subscriber?**

[Claim online access](#)

**Have a free trial code?**

[Activate your free trial](#)

---

### The Lancet Journals

The Lancet  
The Lancet Diabetes &  
Endocrinology  
The Lancet Global Health  
The Lancet Infectious Diseases  
The Lancet Neurology  
EBioMedicine

The Lancet Haematology  
The Lancet HIV  
The Lancet Oncology  
The Lancet Psychiatry  
The Lancet Respiratory Medicine

### Information & Support

About Us  
Information for Authors  
Information for Readers  
The Lancet Careers  
Customer Service  
Contact Us  
Privacy Policy  
Terms and Conditions

### Subscription

Your Account  
Subscription Options  
Existing Print Subscribers

---

Copyright © 2016 Elsevier Limited except certain content provided by third parties.  
The Lancet is a trade mark of RELX Intellectual Properties SA, used under license.  
The Lancet.com website is operated by Elsevier Inc. The content on this site is intended for health professionals.  
Cookies are set by this site. To decline them or learn more, visit our [Cookies page](#).